Trials / Completed
CompletedNCT01961947
Study of ASP7374, Cell-culture-derived Influenza Vaccine
Phase 3 Study of ASP7374 -Approved Egg-derived Vaccine Controlled, Double-blind, Parallel Group Study in Adults ≥20 and <65 Years of Age-
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 900 (actual)
- Sponsor
- UMN Pharma Inc. · Industry
- Sex
- All
- Age
- 20 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare immunogenicity and safety of ASP7374 (cell-culture derived influenza vaccine) with those of approved egg-derived trivalent inactivated vaccine (TIV) in adults ≥20 and \<65 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ASP7374 | subcutaneous |
| BIOLOGICAL | approved egg-derived TIV | subcutaneous |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2013-11-01
- Completion
- 2013-11-01
- First posted
- 2013-10-14
- Last updated
- 2017-09-29
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01961947. Inclusion in this directory is not an endorsement.